OncoMatch/Clinical Trials/NCT05429632
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Is NCT05429632 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies mocravimod for adult acute myeloid leukemia.
Treatment: mocravimod — This is a multi-center, randomized, double-blinded, placebo controlled trial.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Kidney function
estimated creatinine clearance < 45 mL/min by the Cockcroft-Gault formula [excluded]
Liver function
aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN); or total bilirubin > 1.5 mg/dL [excluded]
Cardiac function
Cardiac dysfunction [excluded]
Cardiac/pulmonary/hepatic/renal dysfunction. Hepatic dysfunction as defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN); or total bilirubin > 1.5 mg/dL. Renal dysfunction with estimated creatinine clearance < 45 mL/min by the Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Hospital (UAB Hospital) · Birmingham, Alabama
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- City of Hope Comprehensive Cancer Center - Duarte · Duarte, California
- University of California Los Angeles (UCLA) - David Geffen School of Medicine · Los Angeles, California
- UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify